COMPOSITION FOR ENHANCING EXERCISE ABILITY OR ANTI-FATIGUE COMPRISING NOVEL GINSENOSIDE

• US 20200131222A1
• Filed: 10/29/2019
• Published: 04/30/2020
• Est. Priority Date: 10/31/2018
• Status: Active Grant

• Current Assignee: Amore Pacific Corporation
• Original Assignee: Amore Pacific Corporation
• Inventors: HONG, Yong Deog, JEONG, Hyun Woo
• Granted Patent: US 11,000,538 B2
• Time in Patent Office: Days
• CPC Class Codes: A23L 33/105 Plant extracts, their artificial duplicates or their derivatives
• CPC Class Codes: A23V 2002/00 Food compositions, function of food ingredients or processes for food or foodstuffs
• CPC Class Codes: A23V 2200/31 having an effect on comfort perception and well-being
• CPC Class Codes: A23V 2200/316 having an effect on regeneration or building of ligaments or muscles
• CPC Class Codes: A23V 2250/2124 Ginseng
• CPC Class Codes: A61K 31/7048 having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin , digitoxin or digoxin
• CPC Class Codes: A61K 36/258 Panax (ginseng)
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61K 9/0029 Parenteral nutrition; Parenteral nutrition compositions as drug carriers
• CPC Class Codes: A61K 9/0053 Mouth and digestive tract, i.e. intraoral and peroral administration rectal administration A61K9/0031
• CPC Class Codes: A61K 9/0056 Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
• CPC Class Codes: A61K 9/0095 Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006
• CPC Class Codes: A61K 9/1652 Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin homeopathic globules A61K9/1623
• CPC Class Codes: A61K 9/2059 Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
• CPC Class Codes: A61K 9/4866 Organic macromolecular compounds
• CPC Class Codes: A61P 21/06 Anabolic agents androgens A61P5/26
• CPC Class Codes: C07J 17/005 Glycosides

Abstract

The present specification relates to a composition containing novel (20S,24R)-6-O-β-D-glucopyranosyl(1->2)-β-D-glucopyranoside-dammar-3-one-20,24-epoxy-6a,12b,25-triol, a pharmaceutically acceptable salt thereof, a hydrate or a solvate thereof as an active ingredient. The composition exhibits an excellent exercise ability enhancing effect and anti-fatigue effect.

Claims

1. A method of enhancing exercise ability or anti-fatigue comprising administering to a subject in need thereof an effective amount of (20S,24R)-6-O-β

-D-glucopyranosyl(1->

2)-β

-D-glucopyranoside-dammar-3-one-20,24-epoxy-6a,12b,25-triol, a pharmaceutically acceptable salt thereof, a hydrate or a solvate thereof.

2. The method of claim 1, wherein the (20S,24R)-6-O-β

-D-glucopyranosyl(1->

2)-β

-D-glucopyranoside-dammar-3-one-20,24-epoxy-6a,12b,25-triol has the structure of following formula 1;

3. The method of claim 1, wherein the (20S,24R)-6-O-β

-D-glucopyranosyl(1->

2)-β

-D-glucopyranoside-dammar-3-one-20,24-epoxy-6a,12b,25-triol is extracted from ginseng seed.

4. The method of claim 1, wherein the method is for one or more of muscle regeneration promotion, muscle augmentation, muscle strengthening, the prevention or improvement of sarcopenia, and fatigue recovery promotion and lactic acid metabolism control.

5. The method of claim 1, wherein the (20S,24R)-6-O-β

-D-glucopyranosyl(1->

2)-β

-D-glucopyranoside-dammar-3-one-20,24-epoxy-6a,12b,25-triol, a pharmaceutically acceptable salt thereof, a hydrate, or a solvate thereof promotes the production of mitochondria in myocytes.

6. The method of claim 1, wherein the (20S,24R)-6-O-β

-D-glucopyranosyl(1->

2)-β

-D-glucopyranoside-dammar-3-one-20,24-epoxy-6a,12b,25-triol, a pharmaceutically acceptable salt thereof, a hydrate, or a solvate thereof promotes the fatty acid oxidation in myocytes.

7. The method of claim 1, wherein the (20S,24R)-6-O-β

-D-glucopyranosyl(1->

2)-β

-D-glucopyranoside-dammar-3-one-20,24-epoxy-6a,12b,25-triol, a pharmaceutically acceptable salt thereof, a hydrate, or a solvate thereof reduces the plasma lactate in blood produced by exercise

8. The method of claim 1, wherein the dose of the (20S,24R)-6-O-β

-D-glucopyranosyl(1->

2)-β

-D-glucopyranoside-dammar-3-one-20,24-epoxy-6a,12b,25-triol, a pharmaceutically acceptable salt thereof, a hydrate, or a solvate thereof is 0.5 mg/kg/day to 10 g/kg/day.

9. The method of claim 1, wherein the method comprises transdermal administration of the (20S,24R)-6-O-β

-D-glucopyranosyl(1->

2)-β

-D-glucopyranoside-dammar-3-one-20,24-epoxy-6a,12b,25-triol, a pharmaceutically acceptable salt thereof, a hydrate, or a solvate thereof.

10. The method of claim 1, wherein the method comprises oral or parenteral administration of the (20S,24R)-6-O-β

-D-glucopyranosyl(1->

2)-β

-D-glucopyranoside-dammar-3-one-20,24-epoxy-6a,12b,25-triol, a pharmaceutically acceptable salt thereof, a hydrate or a solvate thereof.